These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23321955)

  • 1. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
    Bilcke J; van Hoek AJ; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
    van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
    Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
    van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
    EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Kim S; Choi JK; Suh J; Park SH; Lee J
    Vaccine; 2024 Jul; 42(19):4046-4055. PubMed ID: 38762358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
    Goldman GS; King PG
    Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
    Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.
    Goldman GS; King PG
    Vaccine; 2013 Mar; 31(13):1680-94. PubMed ID: 22659447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
    Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
    BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
    van Hoek AJ; Melegaro A; Zagheni E; Edmunds WJ; Gay N
    Vaccine; 2011 Mar; 29(13):2411-20. PubMed ID: 21277405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
    Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
    Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
    Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
    Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
    PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
    Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
    Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
    Goldman GS
    Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of varicella vaccination in Canada.
    Brisson M; Edmunds WJ
    Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the impact of varicella vaccination on varicella and zoster.
    Karhunen M; Leino T; Salo H; Davidkin I; Kilpi T; Auranen K
    Epidemiol Infect; 2010 Apr; 138(4):469-81. PubMed ID: 19796447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
    Melegaro A; Marziano V; Del Fava E; Poletti P; Tirani M; Rizzo C; Merler S
    BMC Med; 2018 Jul; 16(1):117. PubMed ID: 30012132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.